Summary
Signal Breakdown
6 verified publisher articles from recent coverage.
Limited TV coverage this week.
3 verified related videos from the past week.
GDELT tone + context across verified sources.
What’s Driving Sentiment
Bullish Signals
- Phase 3 INTerpath‑001 showed Intismeran plus Keytruda cut recurrence/death risk by 42% and was accepted at NEJM.
- ESMO/Phase 1‑3 data reported durable first‑line activity for Lilly's olomorasib combined with Keytruda in KRAS G12C NSCLC.
- Merck's last quarter revenue rose 5.07% to $16.61B, slightly topping the $16.37B consensus.
Risk Factors
- Mondrian cut its Merck stake by 60.4%, selling 889,899 shares in Q3, which may signal reduced institutional demand.
- Leaks of partial Moderna‑Merck vaccine data sparked stock sell‑offs and investor caution ahead of formal ESMO presentations.
- Analysts flagged Keytruda's 2028 patent loss and are watching whether newer launches can offset potential revenue declines.
Evidence
- 2026-10-26Source: TIINGO
Summary: Merck & Co. (MRK) is scheduled to report quarterly earnings on Thursday, mentioned alongside Eli Lilly and AbbVie in a weekly pharma earnings and regulatory roundup.
Neutral - 2026-10-25Source: TIINGO
Summary: Intismeran plus Keytruda reduced recurrence/death risk by 42% and distant metastasis/death risk by 38% in resected stage IIB–IV melanoma (Phase 3 INTerpath-001); NEJM acceptance; supports Merck developing a personalized adjuvant melanoma backbone despite higher treatment-related events and manufacturing complexity.
Bullish - 2026-10-25Source: TIINGO
Summary: Merck (MRK) reports Q3 results Oct. 29; last quarter revenue rose 5.07% to $16.61B vs. $16.37B consensus. Keytruda remains core, with analysts watching growth of newer launches to offset Keytruda’s 2028 patent loss.
Neutral - 2026-10-25Source: TIINGO
Summary: Signaturefd LLC increased its Merck stake 7.4% to 61,332 shares, buying 4,208 shares in Q3 per a 13F filing — modest institutional buying; unlikely to materially affect Merck's fundamentals or stock performance.
Neutral - 2026-10-25Source: TIINGO
Summary: Mondrian Investment Partners sold 889,899 Merck (MRK) shares in Q3, cutting its stake by 60.4% to 584,046 shares, which now represent about 1.8% of the fund’s portfolio — a potentially negative signal for MRK stock demand.
Bearish - 2026-10-25Source: TIINGO
Summary: Lilly presented Phase 1/2 and Phase 3 safety‑lead‑in data at ESMO 2026 showing durable first‑line activity for olomorasib in combination with Merck's anti‑PD‑1 KEYTRUDA (pembrolizumab) in KRAS G12C‑mutant non‑small cell lung cancer without chemotherapy. Positive combination signals could broaden KEYTRUDA use in first‑line KRAS G12C disease, which would be favorable for Merck's pembrolizumab franchise.
Bullish
Showing 6 of 6 verified news articles
- No current evidence is available for this source.
No current verified Archive TV segments
Summary: Discusses leaked Moderna and Merck melanoma vaccine data praised by oncologists but triggering a stock sell-off and investor caution ahead of the formal ESMO presentation.
NeutralSummary: Merck & Co. is mentioned after its shares fell when trial data for a personalized melanoma vaccine (with Moderna) produced mixed investor reaction despite Keytruda combo reducing recurrence and spread.
BearishSummary: Passing mention: Moderna's cancer vaccine was developed with Merck, and a leak of partial data hurt Moderna shares despite later positive full results.
Neutral
Showing 3 of 3 verified videos
Formula & Methodology
- News
- GDELT discovers coverage; only publisher passages that directly name the company qualify as news evidence.
- TV
- Internet Archive TV captions are retained only with a match-centered quote that directly names the company.
- Video
- Recent Bullish Gator videos tagged to the company; the item summary and publisher label feed the judge.
- Holistic AI judge
- A single Azure OpenAI call reads the news, television, and video evidence together and returns the rating, a 0–100 composite, and a short rationale. Thresholds are enum-only: 65+ Bullish, 35 or lower Bearish, Neutral in between.
Data Source
News evidence comes from the GDELT Global Knowledge Graph (via BigQuery); TV evidence from the Internet Archive TV News Archive; video evidence from recent Bullish Gator video coverage. Azure OpenAI filters per-article relevance and serves as the holistic AI judge that produces the composite rating. Portions use data from The GDELT Project under open data terms. This page is informational analysis, not investment advice. See Financial Disclaimer.